Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases

Gastroenterology

Volumn 152, Issue 2, 2017, Pages 415-429.e15

  Cheifetz, Adam S ^a   Gianotti, Robert ^a   Luber, Raphael ^b   Gibson, Peter R ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Acupuncture; Exercise; Herbal Medicine; Probiotics

Indexed keywords

CANNABIS; CURCUMIN; FISH OIL; PROBIOTIC AGENT; TURMERIC; PLANT MEDICINAL PRODUCT;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTICLE; DIET SUPPLEMENTATION; DRUG EFFICACY; EXERCISE; GASTROENTEROLOGIST; HUMAN; INFLAMMATORY BOWEL DISEASE; MOXIBUSTION; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; TRICHURIS SUIS; ANIMAL; COGNITIVE THERAPY; DIETARY SUPPLEMENT; HYPNOSIS; INFLAMMATORY BOWEL DISEASES; KINESIOTHERAPY; MINDFULNESS; PROCEDURES; TREATMENT OUTCOME; TRICHURIS; YOGA;

ACUPUNCTURE THERAPY; ANIMALS; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; EXERCISE THERAPY; HUMANS; HYPNOSIS; INFLAMMATORY BOWEL DISEASES; MIND-BODY THERAPIES; MINDFULNESS; MOXIBUSTION; PLANT PREPARATIONS; PROBIOTICS; RELAXATION THERAPY; TREATMENT OUTCOME; TRICHURIS; YOGA;

EID: 85007504894     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.004     Document Type: Article

References (221)

1. 1 Koning, M., Ailabouni, R., Gearry, R.B., et al. Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study. Inflamm Bowel Dis 19 (2013), 767–778.
2. 2 Mountifield, R., Andrews, J.M., Mikocka-Walus, A., et al. Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in inflammatory bowel disease. J Crohns Colitis 8 (2014), 1723–1729.
3. 3 Hung, A., Kang, N., Bollom, A., et al. Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Dig Dis Sci 60 (2015), 1883–1888.
4. 4 Mountifield, R., Andrews, J.M., Mikocka-Walus, A., et al. Doctor communication quality and friends’ attitudes influence complementary medicine use in inflammatory bowel disease. World J Gastroenterol 21 (2015), 3663–3670.
5. 5 Park, D.I., Cha, J.M., Kim, H.S., et al. Predictive factors of complementary and alternative medicine use for patients with inflammatory bowel disease in Korea. Complement Ther Med 22 (2014), 87–93.
6. 6 Abitbol, V., Lahmek, P., Buisson, A., et al. Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey. Eur J Gastroenterol Hepatol 26 (2014), 288–294.
7. 7 Lindberg, A., Fossum, B., Karlen, P., et al. Experiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study. BMC Complement Altern Med, 14, 2014, 407.
8. 8 Gallinger, Z.R., Nguyen, G.C., Practices and attitudes toward complementary and alternative medicine in inflammatory bowel disease: a survey of gastroenterologists. J Complement Integr Med 11 (2014), 297–303.
9. 9 Gallinger, Z., Bressler, B., Devlin, S.M., et al. A survey of perceptions and practices of complementary alternative medicine among Canadian gastroenterologists. Can J Gastroenterol Hepatol 28 (2014), 45–49.
10. 10 Serpico, M., Boyle, B., Kemper, K.J., et al. Complementary and alternative medicine use in children with inflammatory bowel diseases: a single center survey. J Pediatr Gastroenterol Nutr 63 (2016), 651–665.
11. 11 Rawsthorne, P., Clara, I., Graff, L.A., et al. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut 61 (2012), 521–527.
12. 12 Opheim, R., Hoivik, M.L., Solberg, I.C., et al. Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN). J Crohns Colitis 6 (2012), 345–353.
13. 13 Fernandez, A., Barreiro-de Acosta, M., Vallejo, N., et al. Complementary and alternative medicine in inflammatory bowel disease patients: frequency and risk factors. Dig Liver Dis 44 (2012), 904–908.
14. 14 Langhorst, J., Anthonisen, I.B., Steder-Neukamm, U., et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 11 (2005), 287–295.
15. 15 Agathou, C.L., Beales, I.L., Factors associated with the use of probiotics in patients with inflammatory bowel disease. F1000Res, 2, 2013, 69.
16. 16 Ceballos, C., Bao, R., Dunkin, D., et al. Complementary and alternative medicine use at a single pediatric inflammatory bowel disease center. Gastroenterol Nurs 37 (2014), 265–271.
17. 17 Weizman, A.V., Ahn, E., Thanabalan, R., et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 35 (2012), 342–349.
18. 18 Wong, A.P., Clark, A.L., Garnett, E.A., et al. Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey. J Pediatr Gastroenterol Nutr 48 (2009), 55–60.
19. 19 Gerich, M.E., Isfort, R.W., Brimhall, B., et al. Medical marijuana for digestive disorders: high time to prescribe?. Am J Gastroenterol 110 (2015), 208–214.
20. 20 Izzo, A.A., Sharkey, K.A., Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126 (2010), 21–38.
21. 21 Fichna, J., Bawa, M., Thakur, G.A., et al. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. PLoS One, 9, 2014, e109115.
22. 22 Wallace, J.L., Flannigan, K.L., McKnight, W., et al. Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract. J Physiol Pharmacol 64 (2013), 167–175.
23. 23 Borrelli, F., Fasolino, I., Romano, B., et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 85 (2013), 1306–1316.
24. 24 Singh, U.P., Singh, N.P., Singh, B., et al. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258 (2012), 256–267.
25. 25 Marquez, L., Suarez, J., Iglesias, M., et al. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One, 4, 2009, e6893.
26. 26 Whiting, P.F., Wolff, R.F., Deshpande, S., et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313 (2015), 2456–2473.
27. 27 Weiss, A., Friedenberg, F., Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend 156 (2015), 84–89.
28. 28 Ravikoff Allegretti, J., Courtwright, A., Lucci, M., et al. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis 19 (2013), 2809–2814.
29. 29 Lal, S., Prasad, N., Ryan, M., et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 23 (2011), 891–896.
30. 30 Storr, M., Devlin, S., Kaplan, G.G., et al. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis 20 (2014), 472–480.
31. 31 Lahat, A., Lang, A., Ben-Horin, S., Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 85 (2012), 1–8.
32. 32 Naftali, T., Lev, L.B., Yablecovitch, D., et al. Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 13 (2011), 455–458.
33. 33 Naftali, T., Bar-Lev Schleider, L., Dotan, I., et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 11 (2013), 1276–1280.e1.
34. 34 Hall, W., Degenhardt, L., Adverse health effects of non-medical cannabis use. Lancet 374 (2009), 1383–1391.
35. 35 Hoffmann, D.E., Weber, E., Medical marijuana and the law. N Engl J Med 362 (2010), 1453–1457.
36. 36 Annas, G.J., Medical marijuana, physicians, and state law. N Engl J Med 371 (2014), 983–985.
37. 37 Sugimoto, K., Hanai, H., Tozawa, K., et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123 (2002), 1912–1922.
38. 38 Venkataranganna, M.V., Rafiq, M., Gopumadhavan, S., et al. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 13 (2007), 1103–1107.
39. 39 Binion, D.G., Otterson, M.F., Rafiee, P., Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57 (2008), 1509–1517.
40. 40 Lang, A., Salomon, N., Wu, J.C., et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol 13 (2015), 1444–1449.e1.
41. 41 Hanai, H., Iida, T., Takeuchi, K., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006), 1502–1506.
42. 42 Moss, A.C., Curcumin for maintenance therapy in ulcerative colitis. Clin Gastroenterol Hepatol, 5, 2007, 642.
43. 43 Suskind, D.L., Wahbeh, G., Burpee, T., et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr 56 (2013), 277–279.
44. 44 Singla, V., Pratap Mouli, V., Garg, S.K., et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis 8 (2014), 208–214.
45. 45 Calder, P.C., Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52 (2008), 885–897.
46. 46 Bento, A.F., Claudino, R.F., Dutra, R.C., et al. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol 187 (2011), 1957–1969.
47. 47 Marcon, R., Bento, A.F., Dutra, R.C., et al. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J Immunol 191 (2013), 4288–4298.
48. 48 Cho, J.Y., Chi, S.G., Chun, H.S., Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol Nutr Food Res 55 (2011), 239–246.
49. 49 Camuesco, D., Comalada, M., Concha, A., et al. Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin Nutr 25 (2006), 466–476.
50. 50 Camuesco, D., Galvez, J., Nieto, A., et al. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr 135 (2005), 687–694.
51. 51 Martin, F.P., Lichti, P., Bosco, N., et al. Metabolic phenotyping of an adoptive transfer mouse model of experimental colitis and impact of dietary fish oil intake. J Proteome Res 14 (2015), 1911–1919.
52. 52 Bosco, N., Brahmbhatt, V., Oliveira, M., et al. Effects of increase in fish oil intake on intestinal eicosanoids and inflammation in a mouse model of colitis. Lipids Health Dis, 12, 2013, 81.
53. 53 Marion-Letellier, R., Savoye, G., Beck, P.L., et al. Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis 19 (2013), 650–661.
54. 54 Almallah, Y.Z., Ewen, S.W., El-Tahir, A., et al. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. J Clin Immunol 20 (2000), 68–76.
55. 55 Zhao, Y., Joshi-Barve, S., Barve, S., et al. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 23 (2004), 71–78.
56. 56 Stenson, W.F., Cort, D., Rodgers, J., et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116 (1992), 609–614.
57. 57 Aslan, A., Triadafilopoulos, G., Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 87 (1992), 432–437.
58. 58 Nielsen, A.A., Jorgensen, L.G., Nielsen, J.N., et al. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol Ther 22 (2005), 1121–1128.
59. 59 Feagan, B.G., Sandborn, W.J., Mittmann, U., et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 299 (2008), 1690–1697.
60. 60 Lorenz-Meyer, H., Bauer, P., Nicolay, C., et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 31 (1996), 778–785.
61. 61 Belluzzi, A., Brignola, C., Campieri, M., et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334 (1996), 1557–1560.
62. 62 Middleton, S.J., Naylor, S., Woolner, J., et al. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther 16 (2002), 1131–1135.
63. 63 Loeschke, K., Ueberschaer, B., Pietsch, A., et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 41 (1996), 2087–2094.
64. 64 Hawthorne, A.B., Daneshmend, T.K., Hawkey, C.J., et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33 (1992), 922–928.
65. 65 Salomon, P., Kornbluth, A.A., Janowitz, H.D., Treatment of ulcerative colitis with fish oil n–3-omega-fatty acid: an open trial. J Clin Gastroenterol 12 (1990), 157–161.
66. 66 Almallah, Y.Z., Richardson, S., O'Hanrahan, T., et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol 93 (1998), 804–809.
67. 67 Greenfield, S.M., Green, A.T., Teare, J.P., et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 7 (1993), 159–166.
68. 68 Ben-Arye, E., Goldin, E., Wengrower, D., et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37 (2002), 444–449.
69. 69 Langmead, L., Feakins, R.M., Goldthorpe, S., et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 19 (2004), 739–747.
70. 70 Omer, B., Krebs, S., Omer, H., et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14 (2007), 87–95.
71. 71 Krebs, S., Omer, T.N., Omer, B., Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - a controlled clinical trial. Phytomedicine 17 (2010), 305–309.
72. 72 Sandborn, W.J., Targan, S.R., Byers, V.S., et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 108 (2013), 90–98.
73. 73 Tang, T., Targan, S.R., Li, Z.S., et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 33 (2011), 194–202.
74. 74 Calabrese, C., Berman, S.H., Babish, J.G., et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 14 (2000), 333–338.
75. 75 Cordina, C., Shaikh, I., Shrestha, S., et al. Probiotics in the management of gastrointestinal disease: analysis of the attitudes and prescribing practices of gastroenterologists and surgeons. J Dig Dis 12 (2011), 489–496.
76. 76 Petrof, E.O., Kojima, K., Ropeleski, M.J., et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127 (2004), 1474–1487.
77. 77 Ng, S.C., Plamondon, S., Kamm, M.A., et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16 (2010), 1286–1298.
78. 78 Mennigen, R., Nolte, K., Rijcken, E., et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296 (2009), G1140–G1149.
79. 79 Rachmilewitz, D., Katakura, K., Karmeli, F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004), 520–528.
80. 80 Gionchetti, P., Rizzello, F., Venturi, A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000), 305–309.
81. 81 Shen, J., Zuo, Z.X., Mao, A.P., Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20 (2014), 21–35.
82. 82 Steed, H., Macfarlane, G.T., Blackett, K.L., et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 32 (2010), 872–883.
83. 83 Malchow, H.A., Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?. J Clin Gastroenterol 25 (1997), 653–658.
84. 84 Schultz, M., Timmer, A., Herfarth, H.H., et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol, 4, 2004, 5.
85. 85 Prantera, C., Scribano, M.L., Falasco, G., et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51 (2002), 405–409.
86. 86 Fedorak, R.N., Feagan, B.G., Hotte, N., et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 928–935.e2.
87. 87 Tursi, A., Brandimarte, G., Papa, A., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105 (2010), 2218–2227.
88. 88 Sood, A., Midha, V., Makharia, G.K., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7 (2009), 1202–1209 1209.e1.
89. 89 Miele, E., Pascarella, F., Giannetti, E., et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104 (2009), 437–443.
90. 90 Huynh, H.Q., deBruyn, J., Guan, L., et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 15 (2009), 760–768.
91. 91 Bibiloni, R., Fedorak, R.N., Tannock, G.W., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100 (2005), 1539–1546.
92. 92 Tursi, A., Brandimarte, G., Giorgetti, G.M., et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10 (2004), Pi126–Pi131.
93. 93 Kruis, W., Schutz, E., Fric, P., et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11 (1997), 853–858.
94. 94 Kruis, W., Fric, P., Pokrotnieks, J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004), 1617–1623.
95. 95 Mardini, H.E., Grigorian, A.Y., Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis 20 (2014), 1562–1567.
96. 96 Bressler, B., Marshall, J.K., Bernstein, C.N., et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 148 (2015), 1035–1058 e3.
97. 97 Mimura, T., Rizzello, F., Helwig, U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004), 108–114.
98. 98 Shen, B., Brzezinski, A., Fazio, V.W., et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 22 (2005), 721–728.
99. 99 Gionchetti, P., Rizzello, F., Helwig, U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003), 1202–1209.
100. 100 Gionchetti, P., Rizzello, F., Morselli, C., et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 50 (2007), 2075–2084.
101. 101 Singh, S., Sharma, P.K., Loftus, E.V. Jr., et al. Meta-analysis: serological markers and the risk of acute and chronic pouchitis. Aliment Pharmacol Ther 37 (2013), 867–875.
102. 102 Hashavia, E., Dotan, I., Rabau, M., et al. Risk factors for chronic pouchitis after ileal pouch-anal anastomosis: a prospective cohort study. Colorectal Dis 14 (2012), 1365–1371.
103. 103 Weinstock, J.V., Elliott, D.E., Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol 43 (2013), 245–251.
104. 104 Taghipour, N., Aghdaei, H.A., Haghighi, A., et al. Potential treatment of inflammatory bowel disease: a review of helminths therapy. Gastroenterol Hepatol Bed Bench 7 (2014), 9–16.
105. 105 Elliott, D.E., Urban, J.J., Argo, C.K., et al. Does the failure to acquire helminthic parasites predispose to Crohn's disease?. FASEB J 14 (2000), 1848–1855.
106. 106 Kuijk, L.M., Klaver, E.J., Kooij, G., et al. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol Immunol 51 (2012), 210–218.
107. 107 Klaver, E.J., Kuijk, L.M., Laan, L.C., et al. Trichuris suis-induced modulation of human dendritic cell function is glycan-mediated. Int J Parasitol 43 (2013), 191–200.
108. 108 Hoeksema, M.A., Laan, L.C., Postma, J.J., et al. Treatment with Trichuris suis soluble products during monocyte-to-macrophage differentiation reduces inflammatory responses through epigenetic remodeling. FASEB J 30 (2016), 2826–2836.
109. 109 Ottow, M.K., Klaver, E.J., van der Pouw Kraan, T.C., et al. The helminth Trichuris suis suppresses TLR4-induced inflammatory responses in human macrophages. Genes Immun 15 (2014), 477–486.
110. 110 Summers, R.W., Elliott, D.E., Qadir, K., et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98 (2003), 2034–2041.
111. 111 Khan, W.I., Blennerhasset, P.A., Varghese, A.K., et al. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 70 (2002), 5931–5937.
112. 112 Reardon, C., Sanchez, A., Hogaboam, C.M., et al. Tapeworm infection reduces epithelial ion transport abnormalities in murine dextran sulfate sodium-induced colitis. Infect Immun 69 (2001), 4417–4423.
113. 113 Daveson, A.J., Jones, D.M., Gaze, S., et al. Effect of hookworm infection on wheat challenge in celiac disease–a randomised double-blinded placebo controlled trial. PLoS One, 6, 2011, e17366.
114. 114 Summers, R.W., Elliott, D.E., Urban, J.F. Jr., et al. Trichuris suis therapy in Crohn's disease. Gut 54 (2005), 87–90.
115. 115 Summers, R.W., Elliott, D.E., Urban, J.F. Jr., et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005), 825–832.
116. 116 Shang, H.X., Wang, A.Q., Bao, C.H., et al. Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients. World J Gastroenterol 21 (2015), 4986–4996.
117. 117 Zhao, C., Bao, C., Li, J., et al. Moxibustion and acupuncture ameliorate Crohn's disease by regulating the balance between Th17 and Treg cells in the intestinal mucosa. Evid Based Complement Alternat Med, 2015, 2015, 938054.
118. 118 Zhou, E.H., Liu, H.R., Wu, H.G., et al. Down-regulation of protein and mRNA expression of IL-8 and ICAM-1 in colon tissue of ulcerative colitis patients by partition-herb moxibustion. Dig Dis Sci 54 (2009), 2198–2206.
119. 119 Ji, J., Lu, Y., Liu, H., et al. Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2013, 2013, 158352.
120. 120 Joos, S., Brinkhaus, B., Maluche, C., et al. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion 69 (2004), 131–139.
121. 121 Joos, S., Wildau, N., Kohnen, R., et al. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 41 (2006), 1056–1063.
122. 122 Bao, C.H., Zhao, J.M., Liu, H.R., et al. Randomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease. World J Gastroenterol 20 (2014), 11000–11011.
123. 123 Kurina, L.M., Goldacre, M.J., Yeates, D., et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 55 (2001), 716–720.
124. 124 Mizrahi, M.C., Reicher-Atir, R., Levy, S., et al. Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychol Health 27 (2012), 1463–1479.
125. 125 Bernstein, C.N., Singh, S., Graff, L.A., et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 105 (2010), 1994–2002.
126. 126 Maunder, R.G., Evidence that stress contributes to inflammatory bowel disease: evaluation, synthesis, and future directions. Inflamm Bowel Dis 11 (2005), 600–608.
127. 127 Levenstein, S., Prantera, C., Varvo, V., et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 95 (2000), 1213–1220.
128. 128 Bonaz, B., Sinniger, V., Hoffmann, D., et al. Chronic vagus nerve stimulation in Crohn's disease: a 6-month follow-up pilot study. Neurogastroenterol Motil 28 (2016), 948–953.
129. 129 Bonaz, B., Sinniger, V., Pellissier, S., Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. J Physiol 594 (2016), 5781–5790.
130. 130 Pavlov, V.A., Wang, H., Czura, C.J., et al. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med 9 (2003), 125–134.
131. 131 Pellissier, S., Dantzer, C., Mondillon, L., et al. Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One, 9, 2014, e105328.
132. 132 Rubio, A., Pellissier, S., Picot, A., et al. The link between negative affect, vagal tone, and visceral sensitivity in quiescent Crohn's disease. Neurogastroenterol Motil 26 (2014), 1200–1203.
133. 133 Meregnani, J., Clarencon, D., Vivier, M., et al. Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Auton Neurosci 160 (2011), 82–89.
134. 134 Keefer, L., Taft, T.H., Kiebles, J.L., et al. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther 38 (2013), 761–771.
135. 135 Miller, V., Whorwell, P.J., Treatment of inflammatory bowel disease: a role for hypnotherapy?. Int J Clin Exp Hypn 56 (2008), 306–317.
136. 136 Milne, B., Joachim, G., Niedhardt, J., A stress management programme for inflammatory bowel disease patients. J Adv Nurs 11 (1986), 561–567.
137. 137 Narula, N., Fedorak, R.N., Exercise and inflammatory bowel disease. Can J Gastroenterol 22 (2008), 497–504.
138. 138 Shephard, R.J., The case for increased physical activity in chronic inflammatory bowel disease: a brief review. Int J Sports Med 37 (2016), 505–515.
139. 139 Klare, P., Nigg, J., Nold, J., et al. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. Digestion 91 (2015), 239–247.
140. 140 Ng, V., Millard, W., Lebrun, C., et al. Low-intensity exercise improves quality of life in patients with Crohn's disease. Clin J Sport Med 17 (2007), 384–388.
141. 141 Loudon, C.P., Corroll, V., Butcher, J., et al. The effects of physical exercise on patients with Crohn's disease. Am J Gastroenterol 94 (1999), 697–703.
142. 142 Robinson, R.J., Krzywicki, T., Almond, L., et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 115 (1998), 36–41.
143. 143 Poitras, V.J., Gray, C.E., Borghese, M.M., et al. Systematic review of the relationships between objectively measured physical activity and health indicators in school-aged children and youth. Appl Physiol Nutr Metab 41 (2016), S197–S239.
144. 144 DeFilippis, E.M., Tabani, S., Warren, R.U., et al. Exercise and self-reported limitations in patients with inflammatory bowel disease. Dig Dis Sci 61 (2016), 215–220.
145. 145 Jee, Y.S., Exercise addiction and rehabilitation. J Exerc Rehabil 12 (2016), 67–68.
146. 146 Korkina, L., Suprun, M., Petrova, A., et al. The protective and healing effects of a natural antioxidant formulation based on ubiquinol and Aloe vera against dextran sulfate-induced ulcerative colitis in rats. Biofactors 18 (2003), 255–264.
147. 147 Park, M.Y., Kwon, H.J., Sung, M.K., Dietary aloin, aloesin, or aloe-gel exerts anti-inflammatory activity in a rat colitis model. Life Sci 88 (2011), 486–492.
148. 148 Langmead, L., Makins, R.J., Rampton, D.S., Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther 19 (2004), 521–527.
149. 149 Anthoni, C., Laukoetter, M.G., Rijcken, E., et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 290 (2006), G1131–G1137.
150. 150 Catanzaro, D., Rancan, S., Orso, G., et al. Boswellia serrata preserves intestinal epithelial barrier from oxidative and inflammatory damage. PLoS One, 10, 2015, e0125375.
151. 151 Krieglstein, C.F., Anthoni, C., Rijcken, E.J., et al. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16 (2001), 88–95.
152. 152 Hartmann, R.M., Fillmann, H.S., Martins, M.I., et al. Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. Phytother Res 28 (2014), 1392–1398.
153. 153 Hartmann, R.M., Morgan Martins, M.I., Tieppo, J., et al. Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid. Dig Dis Sci 57 (2012), 2038–2044.
154. 154 Kiela, P.R., Midura, A.J., Kuscuoglu, N., et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol 288 (2005), G798–G8808.
155. 155 Latella, G., Sferra, R., Vetuschi, A., et al. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest 38 (2008), 410–420.
156. 156 Holtmeier, W., Zeuzem, S., Preiss, J., et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 17 (2011), 573–582.
157. 157 Gupta, I., Parihar, A., Malhotra, P., et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2 (1997), 37–43.
158. 158 Gupta, I., Parihar, A., Malhotra, P., et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67 (2001), 391–395.
159. 159 Liu, Z., Wilson-Welder, J.H., Hostetter, J.M., et al. Prophylactic treatment with Hypoxis hemerocallidea corm (African potato) methanolic extract ameliorates Brachyspira hyodysenteriae-induced murine typhlocolitis. Exp Biol Med (Maywood) 235 (2010), 222–230.
160. 160 Wei, X., Gong, J., Zhu, J., et al. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis. Int Immunopharmacol 8 (2008), 1808–1812.
161. 161 Yu, C., Shan, T., Feng, A., et al. Triptolide ameliorates Crohn's colitis is associated with inhibition of TLRs/NF-kappaB signaling pathway. Fitoterapia 82 (2011), 709–715.
162. 162 Sun, J., Shen, X., Dong, J., et al. Tripterygium wilfordii Hook F as maintenance treatment for Crohn's disease. Am J Med Sci 350 (2015), 345–351.
163. 163 Ren, J., Wu, X., Liao, N., et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res 41 (2013), 176–187.
164. 164 Zhu, W., Li, Y., Gong, J., et al. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis 47 (2015), 14–19.
165. 165 Qian, S.Z., Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 36 (1987), 335–345.
166. 166 Ren, J., Tao, Q., Wang, X., et al. Efficacy of T2 in active Crohn's disease: a prospective study report. Dig Dis Sci 52 (2007), 1790–1797.
167. 167 Chung, K.S., Choi, H.E., Shin, J.S., et al. Chemopreventive effects of standardized ethanol extract from the aerial parts of Artemisia princeps Pampanini cv. Sajabal via NF-kappaB inactivation on colitis-associated colon tumorigenesis in mice. Food Chem Toxicol 75 (2015), 14–23.
168. 168 Ahn, B.O., Ko, K.H., Oh, T.Y., et al. Efficacy of use of colonoscopy in dextran sulfate sodium induced ulcerative colitis in rats: the evaluation of the effects of antioxidant by colonoscopy. Int J Colorectal Dis 16 (2001), 174–181.
169. 169 Wendel, G.H., Maria, A.O., Mohamed, F., et al. Effect of dehydroleucodine in experimental colitis in rats and mice. Pharmacol Res 40 (1999), 339–344.
170. 170 Yang, Z., Ding, J., Yang, C., et al. Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis. Curr Med Chem 19 (2012), 4541–4551.
171. 171 Keefer, L., Kiebles, J.L., Kwiatek, M.A., et al. The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial. Biol Res Nurs 14 (2012), 71–77.
172. 172 Keller, W., Pritsch, M., Von Wietersheim, J., et al. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohn's Disease. J Psychosom Res 56 (2004), 687–696.
173. 173 Shaw, L., Ehrlich, A., Relaxation training as a treatment for chronic pain caused by ulcerative colitis. Pain 29 (1987), 287–293.
174. 174 Jedel, S., Hoffman, A., Merriman, P., et al. A randomized controlled trial of mindfulness-based stress reduction to prevent flare-up in patients with inactive ulcerative colitis. Digestion 89 (2014), 142–155.
175. 175 Elsenbruch, S., Langhorst, J., Popkirowa, K., et al. Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom 74 (2005), 277–287.
176. 176 Sharma, P., Poojary, G., Velez, D.M., et al. Effect of yoga-based intervention in patients with inflammatory bowel disease. Int J Yoga Therap 25 (2015), 101–112.
177. 1 Onken, J.E., Greer, P.K., Calingaert, B., et al. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 126 (2008), 345–352.
178. 2 Aslan, A., Triadafilopoulos, G., Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 87 (1992), 432–437.
179. 3 Stenson, W.F., Cort, D., Rodgers, J., et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116 (1992), 609–614.
180. 4 Greenfield, S.M., Green, A.T., Teare, J.P., et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 7 (1993), 159–166.
181. 5 Middleton, S.J., Naylor, S., Woolner, J., et al. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther 16 (2002), 1131–1135.
182. 6 Almallah, Y.Z., Richardson, S., O'Hanrahan, T., et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol 93 (1998), 804–809.
183. 7 Hawthorne, A.B., Daneshmend, T.K., Hawkey, C.J., et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33 (1992), 922–928.
184. 8 Loeschke, K., Ueberschaer, B., Pietsch, A., et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 41 (1996), 2087–2094.
185. 9 Belluzzi, A., Brignola, C., Campieri, M., et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334 (1996), 1557–1560.
186. 10 Feagan, B.G., Sandborn, W.J., Mittmann, U., et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 299 (2008), 1690–1697.
187. 11 Lorenz-Meyer, H., Bauer, P., Nicolay, C., et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 31 (1996), 778–785.
188. 12 Langmead, L., Feakins, R.M., Goldthorpe, S., et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 19 (2004), 739–747.
189. 13 Tang, T., Targan, S.R., Li, Z.S., et al. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 33 (2011), 194–202.
190. 14 Sandborn, W.J., Targan, S.R., Byers, V.S., et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 108 (2013), 90–98.
191. 15 Gupta, I., Parihar, A., Malhotra, P., et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67 (2001), 391–395.
192. 16 Gupta, I., Parihar, A., Malhotra, P., et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2 (1997), 37–43.
193. 17 Holtmeier, W., Zeuzem, S., Preiss, J., et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 17 (2011), 573–582.
194. 18 Sun, J., Shen, X., Dong, J., et al. Tripterygium wilfordii Hook F as maintenance treatment for Crohn's disease. Am J Med Sci 350 (2015), 345–351.
195. 19 Zhu, W., Li, Y., Gong, J., et al. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis 47 (2015), 14–19.
196. 20 Ren, J., Wu, X., Liao, N., et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res 41 (2013), 176–187.
197. 21 Ben-Arye, E., Goldin, E., Wengrower, D., et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37 (2002), 444–449.
198. 22 Omer, B., Krebs, S., Omer, H., et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14 (2007), 87–95.
199. 23 Krebs, S., Omer, T.N., Omer, B., Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - a controlled clinical trial. Phytomedicine 17 (2010), 305–309.
200. 24 Melinder, C., Hiyoshi, A., Hussein, O., et al. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin Transl Gastroenterol, 6, 2015, e121.
201. 25 Khalili, H., Ananthakrishnan, A.N., Konijeti, G.G., et al. Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses’ Health Study cohorts. BMJ, 347, 2013, f6633.
202. 26 Jones, P.D., Kappelman, M.D., Martin, C.F., et al. Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis 21 (2015), 1063–1071.
203. 27 Bilski, J., Mazur-Bialy, A., Brzozowski, B., et al. Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. Pharmacol Rep 68 (2016), 827–836.
204. 28 Cook, M.D., Allen, J.M., Pence, B.D., et al. Exercise and gut immune function: evidence of alterations in colon immune cell homeostasis and microbiome characteristics with exercise training. Immunol Cell Biol 94 (2016), 158–163.
205. 29 D'Inca, R., Varnier, M., Mestriner, C., et al. Effect of moderate exercise on Crohn's disease patients in remission. Ital J Gastroenterol Hepatol 31 (1999), 205–210.
206. 30 Moses, F.M., Exercise-associated intestinal ischemia. Curr Sports Med Rep 4 (2005), 91–95.
207. 31 Shi, Y., Qi, L., Wang, J., et al. Moxibustion activates mast cell degranulation at the ST25 in rats with colitis. World J Gastroenterol 17 (2011), 3733–3738.
208. 32 Shi, Y., Zhou, E.H., Wu, H.G., et al. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn's disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2. Chin J Integr Med 17 (2011), 212–217.
209. 33 Wang, X.M., Lu, Y., Wu, L.Y., et al. Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis. World J Gastroenterol 18 (2012), 6819–6828.
210. 34 Wu, H.G., Liu, H.R., Tan, L.Y., et al. Electroacupuncture and moxibustion promote neutrophil apoptosis and improve ulcerative colitis in rats. Dig Dis Sci 52 (2007), 379–384.
211. 35 Bao, C.H., Wu, L.Y., Shi, Y., et al. Moxibustion down-regulates colonic epithelial cell apoptosis and repairs tight junctions in rats with Crohn's disease. World J Gastroenterol 17 (2011), 4960–4970.
212. 36 Bao, C.H., Wu, L.Y., Wu, H.G., et al. Moxibustion inhibits apoptosis and tumor necrosis factor-alpha/tumor necrosis factor receptor 1 in the colonic epithelium of Crohn's disease model rats. Dig Dis Sci 57 (2012), 2286–2295.
213. 37 Wu, H.G., Gong, X., Yao, L.Q., et al. Mechanisms of acupuncture and moxibustion in regulation of epithelial cell apoptosis in rat ulcerative colitis. World J Gastroenterol 10 (2004), 682–688.
214. 38 Wang, X., Liu, Y., Dong, H., et al. Herb-partitioned moxibustion regulates the TLR2/NF-kappaB signaling pathway in a rat model of ulcerative colitis. Evid Based Complement Alternat Med, 2015, 2015, 949065.
215. 39 Wu, H.G., Zhou, L.B., Pan, Y.Y., et al. Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines. World J Gastroenterol 5 (1999), 515–517.
216. 40 Goes, A.C., Pinto, F.M., Fernandes, G.C., et al. Electroacupuncture ameliorates experimental colitis induced by TNBS through activation of interleukin-10 and inhibition of iNOS in mice. Acta Cir Bras 29 (2014), 787–793.
217. 41 Han, Y., Ma, T.M., Lu, M.L., et al. Role of moxibustion in inflammatory responses during treatment of rat ulcerative colitis. World J Gastroenterol 20 (2014), 11297–11304.
218. 42 Yan, J., Zhang, H., Chen, C.T., et al. Effects of electroacupuncture at Shangjuxu (ST 37) on interleukin-1beta and interleukin-4 in the ulcerative colitis model rats. J Tradit Chin Med 29 (2009), 60–63.
219. 43 Tian, L., Huang, Y.X., Tian, M., et al. Downregulation of electroacupuncture at ST36 on TNF-alpha in rats with ulcerative colitis. World J Gastroenterol 9 (2003), 1028–1033.
220. 44 Ho, T.Y., Lo, H.Y., Chao, D.C., et al. Electroacupuncture improves trinitrobenzene sulfonic acid-induced colitis, evaluated by transcriptomic study. Evid Based Complement Alternat Med, 2014, 2014, 942196.
221. 45 Kim, H.Y., Hahm, D.H., Pyun, K.H., et al. Effects of acupuncture at GV01 on experimentally induced colitis in rats: possible involvement of the opioid system. Jpn J Physiol 55 (2005), 205–210.